ArticleCommunications medicine2025
Using proteomic biomarkers to estimate acute ischaemic stroke onset time.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of stroke blood biomarker data highlights need for more translational research methods.Nature communications · 2026Pooled it
- Next-Generation Stroke Biomarkers: Bridging the Gap Between Innovation and Translation.Journal of clinical medicine · 2026Review
- Cerebral Infarction: Epidemiology, Classification, Mechanisms, Diagnosis, and Management.MedComm · 2026Review
- Emerging biomarkers in ischemic stroke.Vessel plus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines recommend intravenous thrombolysis (IVT) for acute ischaemic stroke (AIS) patients within 4.5 hour (h) of symptom onset. Our study aims to use proteomic biomarkers to identify AIS patients with an onset time within 4.5 h when the history is not clear.
methodsWe conducted a retrospective case-control study between June 2022 and July 2023 in Ningbo No. 2 Hospital, recruiting 30 AIS patients and 12 controls. Patients with AIS were grouped into early-onset (ES, symptom onset time ≤ 4.5 h, n = 16) and late-onset (LS, symptom onset 4.5-24 h, n = 14). Plasma proteome were identified using mass spectrometry. A stepwise analysis was conducted to screen for candidate proteins. Multiple logistic regression was used to construct various combinations.
resultsHere we show six proteins discriminate ES from LS, with the area under curve (AUC) ranging from 0.897 to 0.951. Protein 4.2 (EPB42) achieves the highest AUC of 0.951 (95% confidence interval 0.882-1), a specificity of 0.929 (0.714-1) and a sensitivity of 0.875 (0.750-1). Ten combinations are derived from these six proteins, of which EPB42 and Phosphatidylethanolamine-binding protein 1 achieve an AUC of 0.991 (0.970-1), a specificity of 0.929 (0.857-1), and a sensitivity of 1 (0.875-1) in differentiating ES from LS.
conclusionsThe six proteins and their combinations show promise as molecular clocks for determining the onset time of AIS in patients whose symptom onset time are unknown, potentially increasing their chances of receiving effective IVT to improve stroke outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.